JP2020532565A - 可逆性リンカーおよびその使用 - Google Patents

可逆性リンカーおよびその使用 Download PDF

Info

Publication number
JP2020532565A
JP2020532565A JP2020513526A JP2020513526A JP2020532565A JP 2020532565 A JP2020532565 A JP 2020532565A JP 2020513526 A JP2020513526 A JP 2020513526A JP 2020513526 A JP2020513526 A JP 2020513526A JP 2020532565 A JP2020532565 A JP 2020532565A
Authority
JP
Japan
Prior art keywords
cells
linker
pmel
compound according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532565A5 (enExample
Inventor
トマス アンドレセン，
トマス アンドレセン，
Original Assignee
トルク セラピューティクス， インコーポレイテッド
トルク セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トルク セラピューティクス， インコーポレイテッド, トルク セラピューティクス， インコーポレイテッド filed Critical トルク セラピューティクス， インコーポレイテッド
Publication of JP2020532565A publication Critical patent/JP2020532565A/ja
Publication of JP2020532565A5 publication Critical patent/JP2020532565A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020513526A 2017-09-05 2018-09-05 可逆性リンカーおよびその使用 Pending JP2020532565A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554067P 2017-09-05 2017-09-05
US62/554,067 2017-09-05
US201862616221P 2018-01-11 2018-01-11
US62/616,221 2018-01-11
PCT/US2018/049594 WO2019050977A1 (en) 2017-09-05 2018-09-05 REVERSIBLE LINKS AND THEIR USE

Publications (2)

Publication Number Publication Date
JP2020532565A true JP2020532565A (ja) 2020-11-12
JP2020532565A5 JP2020532565A5 (enExample) 2021-10-14

Family

ID=65634522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513526A Pending JP2020532565A (ja) 2017-09-05 2018-09-05 可逆性リンカーおよびその使用

Country Status (8)

Country Link
US (2) US11547760B2 (enExample)
EP (1) EP3678704A4 (enExample)
JP (1) JP2020532565A (enExample)
KR (1) KR20210031848A (enExample)
CN (1) CN111432843A (enExample)
AU (1) AU2018328208A1 (enExample)
CA (1) CA3075027A1 (enExample)
WO (1) WO2019050977A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532568A (ja) * 2017-09-05 2020-11-12 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112891556B (zh) * 2021-02-01 2023-03-03 浙江大学医学院附属第一医院 一种单抗类药物口服纳米凝胶及其制备方法
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
CN115785490A (zh) * 2022-11-29 2023-03-14 广西医科大学 一种交联改性的明胶材料及其制备方法
WO2024130179A1 (en) 2022-12-16 2024-06-20 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085269A (en) * 1976-07-27 1978-04-18 Basf Aktiengesellschaft 1,3,5 Tris-(2-chloroformyl-oxyethyl)-isocyanurate
US4549010A (en) * 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
JP2001523637A (ja) * 1997-11-05 2001-11-27 シアウォーター・ポリマーズ，インコーポレイテッド 分解性ハイドロゲルからの修飾ポリエチレングリコール分子の送達
US20140249319A1 (en) * 2013-03-01 2014-09-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
JP2016533344A (ja) * 2013-09-27 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1112021A (en) * 1964-01-02 1968-05-01 Gevaert Photo Prod Nv Polycarbonates with increased crystallizability
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
AU4648697A (en) 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
EP1462802A1 (en) 1998-07-30 2004-09-29 Oakville Trading Hong Kong Limited Method for preparing water-soluble cross-linked conjugates
US6613582B1 (en) 1999-05-25 2003-09-02 Board Of Regents, The University Of Texas System Methods for rapid and efficient protein cross-linking
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
ATE459370T1 (de) 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7604804B2 (en) 2004-02-09 2009-10-20 University Of Maryland Biotechnology Institute Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CA2585664C (en) 2004-11-05 2014-05-20 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
US20080207505A1 (en) 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
WO2008013860A2 (en) 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
KR101316159B1 (ko) 2008-10-24 2013-10-15 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
ES2655592T3 (es) 2010-03-29 2018-02-20 Evonik Corporation Composiciones y métodos para la retención mejorada de una composición farmacéutica en un sitio de administración local
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
US20140081012A1 (en) 2011-02-15 2014-03-20 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
WO2013012961A2 (en) 2011-07-19 2013-01-24 Cellmosaic, Llc Novel crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof
US9511150B2 (en) 2011-07-19 2016-12-06 CellMosaic, Inc. Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
CN108939059B (zh) * 2013-06-14 2022-05-10 康思葆（北京）生物技术有限公司 蛋白-细胞偶联物、其制备方法和用途
US11034752B2 (en) 2015-08-12 2021-06-15 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085269A (en) * 1976-07-27 1978-04-18 Basf Aktiengesellschaft 1,3,5 Tris-(2-chloroformyl-oxyethyl)-isocyanurate
US4549010A (en) * 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
JP2001523637A (ja) * 1997-11-05 2001-11-27 シアウォーター・ポリマーズ，インコーポレイテッド 分解性ハイドロゲルからの修飾ポリエチレングリコール分子の送達
US20140249319A1 (en) * 2013-03-01 2014-09-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
JP2016533344A (ja) * 2013-09-27 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532568A (ja) * 2017-09-05 2020-11-12 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法

Also Published As

Publication number Publication date
EP3678704A4 (en) 2021-09-01
CN111432843A (zh) 2020-07-17
US20230248841A1 (en) 2023-08-10
AU2018328208A1 (en) 2020-04-23
US20210154313A1 (en) 2021-05-27
EP3678704A1 (en) 2020-07-15
CA3075027A1 (en) 2019-03-14
US11547760B2 (en) 2023-01-10
WO2019050977A1 (en) 2019-03-14
KR20210031848A (ko) 2021-03-23

Similar Documents

Publication Publication Date Title
US20230248841A1 (en) Reversible linkers and use thereof
US20230233609A1 (en) Therapeutic protein compositions and methods of making and using the same
US11795463B2 (en) Transglutaminase-mediated conjugation
AU2019303080B2 (en) Fc binding fragments comprising an OX40 antigen-binding site
JP2020503860A (ja) 免疫応答のコンディショナルアゴニスト
JP2013502209A (ja) 標的化イムノコンジュゲート
EP3889183A1 (en) A protein complex comprising an immunocytokine
JP2022512944A (ja) 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
KR20220025739A (ko) T-세포 활성화를 위한 항체
US20220008526A1 (en) Methods and compositions for cancer immunotherapy
JP2023545394A (ja) 抗ｐｄ－ｌ１抗体およびその用途
EP4534558A1 (en) Anti-cd228 antibody and drug conjugate thereof
WO2025092782A1 (en) Combination of antibody-immune agonist conjugate and anti-pd-1 antibody, and use thereof
WO2025217310A1 (en) Pegylated il- 15 receptor alpha cytokines
KR20250172622A (ko) 항-Trop2 항체-자연 살해 세포 접합체 및 이의 용도
CN119233973A (zh) 一种药物化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230427